Types of Research
- (-) Remove 2017 filter 2017
- (-) Remove 2013 filter 2013
- (-) Remove Political Economy & Governance filter Political Economy & Governance
- (-) Remove Aid & Other Development Finance filter Aid & Other Development Finance
- (-) Remove 2018 filter 2018
- (-) Remove Sub-Saharan Africa filter Sub-Saharan Africa
- (-) Remove 2012 filter 2012
- (-) Remove Global filter Global
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
The private sector is the primary investor in health research and development (R&D) worldwide, with investment annual investment exceeding $150 billion, although only an estimated $5.9 billion is focused on diseases that primarily affect low and middle-income countries (LMICs) (West et al., 2017b). Pharmaceutical companies are the largest source of private spending on global health R&D focused on LMICs, providing $5.6 billion of the $5.9 billion in total private global health R&D per year. This report draws on 10-K forms filed by Pharmaceutical companies with the U.S. Securities and Exchange Commission (SEC) in the year 2016 to examine the evidence for five specific disincentives to private sector investment in drugs, vaccines and therapeutics for global health R&D: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed costs for research and manufacturing, and imperfect markets. 10-K reports follow a standard format, including a business section and a risk section which include information on financial performance, investment options, lines of research, promising acquisitions and risk factors (scientific, market, and regulatory). As a result, these filings provide a valuable source of information for analyzing how private companies discuss risks and challenges as well as opportunities associated with global health R&D targeting LMICs.
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
Donor countries and multilateral organizations may pursue multiple goals with foreign aid, including supporting low-income country development for strategic/security purposes (national security, regional political stability) and for short-and long-term economic interests (market development and access, local and regional market stability). While the literature on the effectiveness of aid in supporting progress on different indicators of country development is inconclusive, donors are interested in evidence that aid funding is not permanent but rather contributes to a process by which recipient countries develop to a point that they are economically self-sufficient. In this report, we review the literature on measures of country self-sufficiency and descriptive evidence from illustrative case studies to explore conditions associated with transitions toward self-sufficiency in certain contexts.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
In this brief we analyze patterns of intercropping and differences between intercropped and monocropped plots among smallholder farmers in Tanzania using data from the 2008/2009 wave of the Tanzania National Panel Survey (TZNPS), part of the Living Standards Measurement Study – Integrated Surveys on Agriculture (LSMS-ISA). Intercropping is a planting strategy in which farmers cultivate at least two crops simultaneously on the same plot of land. In this brief we define intercropped plots as those for which respondents answered “yes” to the question “Was cultivation intercropped?” We define “intercropping households” as those households that intercropped at least one plot at any point during the year in comparison to households that did not intercrop any plots. The analysis reveals few significant, consistent productivity benefits to intercropping as currently practiced. Intercropped plots are not systematically more productive (in terms of value produced) than monocropped plots. The most commonly cited reason for intercropping was to provide a substitute crop in the case of crop failure. This suggests that food and income security are primary concerns for smallholder farmers in Tanzania. A separate appendix includes the details for our analyses.
Local crop diversity and crop cultivation patterns among smallholder farmers have implications for two important elements of the design of agricultural interventions in developing countries. First, crop cultivation patterns may aid in targeting by helping to identify geographic areas where improved seed and other productivity enhancing technologies will be most easily applicable. Second, these patterns may help to identify potential unintended consequences of crop interventions focused on a single crop (e.g. maize). This report analyzes the distribution of crop diversity and crop cultivation patterns, and factors that can lead to changes in these patterns among smallholder farmers in Tanzania with a focus on regional patterns of crop cultivation and changes in these patterns over time, the factors that affect crop diversity and changes in crop diversity, and the level of substitutability between crops grown by smallholder farmers. All analysis is based on the Tanzania National Panel Survey (TNPS) datasets from 2008 and 2010. The paper is structured as follows. Section I provides a description of regional patterns of crop cultivation and crop diversity between the two years of the panel. Section II presents background on the theoretical factors affecting crop choice, and presents our findings on the results of a multivariate analysis on the factors contributing to crop diversity. Finally, Section 3 provides a preliminary analysis of the level of substitutability between cereal crop of importance in Tanzania (maize, rice and sorghum/millet) and also between these cereal crops and non-cereal crops.